메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 17, 2009, Pages 2747-2748
Cheaper, faster, better: Chasing the elusive clinical trial end point
Author keywords

[No Author keywords available]
Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SURVIVAL TIME; TREATMENT OUTCOME; COST CONTROL; ECONOMICS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HOSPITAL INFORMATION SYSTEM; NOTE; UNITED STATES;
EID: 67649987114     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.4726     Document Type: Editorial
Times cited : (2)
References (9)
  • 2
    • 0021343213 scopus 로고
    • A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias
    • Simon R, Makuch RW: A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med 3:35-44, 1984
    • (1984) Stat Med , vol.3 , pp. 35-44
    • Simon, R.1    Makuch, R.W.2
  • 3
    • 50449205260 scopus 로고    scopus 로고
    • Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
    • Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 26:3913-3915, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 3913-3915
    • Anderson, J.R.1    Cain, K.C.2    Gelber, R.D.3
  • 4
    • 67649965349 scopus 로고    scopus 로고
    • Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer
    • Halabi S, Vogelzang NJ, Ou SS, et al: Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 27:2766-2771, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 2766-2771
    • Halabi, S.1    Vogelzang, N.J.2    Ou, S.S.3
  • 5
    • 33947355892 scopus 로고    scopus 로고
    • The association between measures of progression and survival in castrate-metastatic prostate cancer
    • Scher HI, Warren M, Heller G: The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 13:1488-1492, 2007
    • (2007) Clin Cancer Res , vol.13 , pp. 1488-1492
    • Scher, H.I.1    Warren, M.2    Heller, G.3
  • 6
    • 0030268577 scopus 로고    scopus 로고
    • Surrogate end points in clinical trials: Are we being misled?
    • Fleming TR, DeMets DL: Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 125:605-613, 1996
    • (1996) Ann Intern Med , vol.125 , pp. 605-613
    • Fleming, T.R.1    DeMets, D.L.2
  • 7
    • 0026573094 scopus 로고
    • Statistical validation of intermediate endpoints for chronic diseases
    • Freedman LS, Graubard BI, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178, 1992
    • (1992) Stat Med , vol.11 , pp. 167-178
    • Freedman, L.S.1    Graubard, B.I.2    Schatzkin, A.3
  • 8
    • 0030771191 scopus 로고    scopus 로고
    • Estimating the proportion of treatment effect explained by a surrogate marker
    • Lin DY, Fleming TR, De Gruttola V: Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16:1515-1527, 1997
    • (1997) Stat Med , vol.16 , pp. 1515-1527
    • Lin, D.Y.1    Fleming, T.R.2    De Gruttola, V.3
  • 9
    • 0024520844 scopus 로고
    • Surrogate endpoints in clinical trials: Definition and operational criteria
    • Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440, 1989
    • (1989) Stat Med , vol.8 , pp. 431-440
    • Prentice, R.L.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.